



**Thiamine Mononitrate (Vitamin B<sub>1</sub>)  
Pyridoxine Hydrochloride (Vitamin B<sub>6</sub>)  
Cyanocobalamin (Vitamin B<sub>12</sub>)**

**MEDINERV FORTE**  
300 mg/100 mg/100 mcg Capsule  
VITAMINS

**PRODUCT DESCRIPTION**

Encapsulated in hard black/red gelatin capsule containing white to off-white powder.

**FORMULATION**

Each capsule contains:

Thiamine Mononitrate (Vit. B<sub>1</sub>), USP ..... 300 mg  
Pyridoxine HCl (Vit. B<sub>6</sub>), USP ..... 100 mg  
Cyanocobalamin (Vit. B<sub>12</sub>), USP ..... 100 mcg

**PHARMACODYNAMICS**

This product contains B-complex vitamins (vitamins B<sub>1</sub>, B<sub>6</sub>, B<sub>12</sub>). These nutrients are required for normal nerve function and are used as adjunct in the management of neuromuscular pain. B-complex vitamins have the following neuromuscular functions/effects:

NUTRIENTS	NEUROMUSCULAR FUNCTION
Thiamine (B <sub>1</sub> )	Involved in the production and release of acetylcholine, neurotransmitter required in conveying signals between cells.
Pyridoxine (B <sub>6</sub> )	Required in the formation of neurotransmitter such as serotonin, gamma amino butyric acid (GABA), dopamine, and epinephrine to facilitate normal nervous system function.
Cyanocobalamin (B <sub>12</sub> )	Required for the synthesis of myelin, the white sheath that surrounds nerve fibers.

**PHARMACOKINETICS**

**Vitamin B<sub>1</sub>.** Small amounts of thiamine are well absorbed from the gastrointestinal tract after oral doses, but the absorption of doses larger than about 5 mg is limited. It is also rapidly absorbed on intramuscular injection. It is widely distributed to most body tissues, and appears in breast milk. Within the cell, thiamine is mostly present as the diphosphate. Thiamine is not stored to any appreciable extent in the body and amounts in excess of the body's requirements are excreted in the urine unchanged or as metabolites.

**Vitamin B<sub>6</sub>.** Pyridoxine, pyridoxal, and pyridoxamine are readily absorbed from the gastrointestinal tract after oral doses and are converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. They are stored mainly in the liver where there is oxidation to 4-pyridoxic acid and other inactive metabolites which are excreted in the urine. As the dose increases, proportionally greater amounts are excreted unchanged in the urine. Pyridoxal crosses the placenta and is distributed into breast milk.

**Vitamin B<sub>12</sub>.** Substances bind to intrinsic factor, a glycoprotein secreted by the gastric mucosa, and are then actively absorbed from the gastrointestinal tract. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with disease or abnormality of the gut, or after gastrectomy. Absorption from the gastrointestinal tract can also occur by passive diffusion, little of the vitamin present in food is absorbed in this manner although the process becomes increasingly important with larger amounts such as those used therapeutically. After intranasal dosage, peak plasma concentrations of cyanocobalamin have been reached in 1 to 2 hours. The bioavailability of the intranasal preparation is about 7 to 11 % of the intramuscular injection. Vitamin B<sub>12</sub> is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins to tissues.

**INDICATIONS**

Neuritis, neuralgia, polyneuritis, lumbago, cervical and shoulder-arm syndrome, rheumatic pains, herpes zoster, alcoholism, cardiac disorders, diabetic neuropathy, encephalopathies, iatrogenic complications arising from INH, reserpine and phenothiazine therapy. Vitamin B deficiencies.

**DOSAGE AND MODE OF ADMINISTRATION:**

As prophylaxis:  
1-2 capsules daily

As therapy:  
2-4 capsules.  
Or as prescribed by a physician.

**PRECAUTIONS**

In patients known to be hypersensitive to any of its content.

**WARNING**

Cyanocobalamin (Vitamin B<sub>12</sub>) should not be given to patients with suspected vitamin B<sub>12</sub> deficiency without first confirming the diagnosis. Regular monitoring of the blood is advisable. Administration of doses greater than 10 µg daily may produce a haematological response in patients with folate deficiency; indiscriminate use may mask the precise diagnosis. Conversely, folate may mask vitamin B<sub>12</sub> deficiency.

**INTERACTIONS**

**Vitamin B<sub>6</sub>.** Pyridoxine reduces the effects of levodopa but this does not occur if a dopa decarboxylase inhibitor is also given. Pyridoxine reduces the activity of alitretamine. It has also been reported to decrease serum concentrations of phenobarbital and phenytoin. Many drugs may increase the requirements for pyridoxine; such drugs hydralazine, isoniazid, penicillamine and oral contraceptives.

**Vitamin B<sub>12</sub>.** Absorption of vitamin B<sub>12</sub> from the gastrointestinal tract may be reduced neomycin, aminosalicylic acid, histamine H<sub>2</sub>-antagonists, omeprazole, and colchicine. Serum concentrations may be decreased by use of oral contraceptives. Many of these interactions are unlikely to be of clinical significance but should be taken into account when performing assays for blood concentrations. Parenteral chloramphenicol may attenuate the effect of vitamin B<sub>12</sub> in anaemia.

**ADVERSE EFFECTS**

**Thiamine Mononitrate (Vit. B<sub>1</sub>)**

Adverse effects with thiamine are rare, but hypersensitivity reactions have occurred. These reactions have ranged in severity from very mild to, very rarely, fatal anaphylactic shock.

**Pyridoxine Hydrochloride (Vit. B<sub>6</sub>)**

Long-term use of large doses of pyridoxine is associated with the development of severe peripheral neuropathies, the dose at which these occur is controversial. Pyridoxine reduces the effects of levodopa, but this does not occur if a dopa decarboxylase inhibitor is also given. Pyridoxine reduces the activity of alitretamine. It has also been reported to decrease serum concentrations of phenobarbital and phenytoin.

Many drugs may increase the requirements for pyridoxine; such drugs include hydralazine, isoniazid, penicillamine, and oral contraceptives.

**Cyanocobalamin (Vit. B<sub>12</sub>)**

Allergic hypersensitivity reactions have occurred rarely after parenteral doses of the vitamin B<sub>12</sub> compounds cyanocobalamin.

**OVERDOSE AND TREATMENT**

**Vitamin B<sub>6</sub>.** Although vitamin B<sub>6</sub> has generally been considered relatively nontoxic, long term (two months or longer) administration of large (megadose) dosages (usually 2 grams or more daily) of vitamin B<sub>6</sub> can cause neurological symptoms manifested as paresthesia (more noticeable at night and limited to the extremities), bone pains (described as lightning, stabbing or shooting like a knitting needle or electric shocks), hyperesthesia (described in burning, pricking, stinging, or itching), muscle weakness (difficulty in running, lifting, climbing stairs and loss of manual dexterity) fasciculation (described as twitching, restlessness or fidgeting), and numbness of the limbs and face.

**CAUTION**

Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.

**ADR REPORTING STATEMENT:**

\*For suspected adverse drug reaction, report to the FDA: [www.fda.gov/ph](http://www.fda.gov/ph)  
Seek medical attention immediately at the first sign of any adverse drug reaction.

**AVAILABILITY**

Blister pack x 10's (Box of 100's)

**STORAGE CONDITION**

Store at temperatures not exceeding 30°C

**REGISTRATION NUMBER**

DRP-887-02

**DATE OF FIRST AUTHORIZATION/ RENEWAL**

September 24, 2008

**DATE OF REVISION**

June 2021

Distributed by:   
**ALTAMEDICA INCORPORATED**  
Rm 410, Manila Astral Tower 1330 Taft Ave.,  
Cor. Padre Faura St., Ermita 073, Brgy. 676,  
Manila, Metro Manila

Manufactured by:  
  
**J.M. TOLMANN**  
LANGRATWIRIA, INC.  
110 North Avenue 3, Alhambra, Q.C.